Hybrid fusion protein transcription regulator to induce interferon target gene expression
View Patent ↗New hybrid or chimeric fusion polypeptide transcription regulators which induce interferon target gene expression are provided for use in anti-viral and anti-proliferative applications. The hybrid fusion proteins comprise the p48 interferon regulatory factor protein, or a functional portion thereof, fused to a transcriptional activation domain (TAD), or a functional portion thereof. More specifically, the p48 interferon regulatory factor protein is fused to a STAT transcriptional activation do main (TAD) (p48-STAT TAD). A particular p48-STAT TAD is p48-S2C, in which S2C is the TAD of STAT2. Another p48-TAD is p48-VP16 TAD, in which p48 is fused to the transcriptional activation domain of the VP16 protein of Herpes Simplex Virus (HSV). The p48-TAD nucleic acid sequences and encoded polypeptides can be employed for anti-viral treatment and for the treatment of cancers, tumors and neoplastic diseases.
1. A hybrid fusion polypeptide selected from the group consisting of the amino acid sequence set forth in SEQ ID NO: 2; and the amino acid sequence set forth in SEQ ID NO: 30.
2. A composition comprising the polypeptide according to claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.
3. A method of producing the hybrid interferon fusion polypeptide according to claim 1 , comprising:
(a) introducing into a host cell, a recombinant expression system containing an open reading frame (ORF) having a polynucleotide sequence which encodes the hybrid fusion polypeptide, wherein the vector is designed to express the ORF in the host cell, and
(b) culturing the host cell under conditions resulting in the expression of the ORF sequence.
4. A method of administering the polypeptide according to claim 1 to a host cell comprising, contacting the host cell with the composition.
5. A method of administering the composition according to claim 2 to a host cell comprising, contacting the host cell with the composition.